Cytokinetics (NASDAQ:CYTK) will announce its earnings results on Wednesday, February 14th. Analysts expect the company to announce earnings of ($0.71) per share for the quarter.
Cytokinetics (NASDAQ:CYTK) opened at $8.40 on Wednesday. The company has a current ratio of 7.60, a quick ratio of 7.60 and a debt-to-equity ratio of 0.14. The stock has a market cap of $452.63, a P/E ratio of -5.06 and a beta of 1.03. Cytokinetics has a 1 year low of $7.00 and a 1 year high of $17.20.
A number of equities analysts have recently issued reports on CYTK shares. HC Wainwright restated a “buy” rating and set a $26.00 target price on shares of Cytokinetics in a research report on Friday, October 27th. Needham & Company LLC lowered shares of Cytokinetics from a “strong-buy” rating to a “buy” rating and lowered their target price for the stock from $22.00 to $12.00 in a research report on Wednesday, November 29th. Morgan Stanley restated an “overweight” rating and set a $17.00 target price (down from $25.00) on shares of Cytokinetics in a research report on Wednesday, November 22nd. ValuEngine lowered shares of Cytokinetics from a “hold” rating to a “sell” rating in a research report on Tuesday, November 21st. Finally, Piper Jaffray Companies restated an “overweight” rating and set a $18.00 target price on shares of Cytokinetics in a research report on Tuesday, November 21st. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating to the stock. Cytokinetics currently has a consensus rating of “Buy” and an average price target of $17.91.
Cytokinetics Company Profile
Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions.
Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with MarketBeat.com's FREE daily email newsletter.